OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development Feb 18, 2021 8:30am EST
OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein Jan 27, 2021 9:00am EST
OncoSec Medical Announces Pricing of $42.0 Million Public Offering of Common Stock Jan 21, 2021 8:30am EST
OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma Jan 08, 2021 9:00am EST
OncoSec Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO™ and Its Gene Electrotransfer Technology Dec 10, 2020 9:00am EST
